AlphaFold predicted structure
RNF125 · Q96EQ8

Mean pLDDT
77.4/ 100
Confident
232 residues
Confidence breakdown
- Very high(≥ 90)41%
- Confident(70–90)29%
- Low(50–70)12%
- Very low(< 50)18%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
ring finger protein 125
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
Beckwith-Wiedemann syndrome (BWS) and other congenital overgrowth disorders
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedFetal anomalies
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedHydrocephalus
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownIntellectual disability
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedDDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownTenorio syndrome
Intellectual disability
Chronic Obstructive Asthma
hereditary disease
hypertrophic cardiomyopathy
neoplasm
hepatocellular carcinoma
asthma
melanoma
maple syrup urine disease
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
E3 ubiquitin-protein ligase RNF125
E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins, such as RIGI, MAVS/IPS1, IFIH1/MDA5, JAK1 and p53/TP53 (PubMed:15843525, PubMed:17460044, PubMed:17643463, PubMed:25591766, PubMed:26027934, PubMed:26471729, PubMed:27411375). Acts as a negative regulator of type I interferon production by mediating ubiquitination of RIGI at 'Lys-181', leading to RIGI degradation (PubMed:17460044, PubMed:26471729). Mediates ubiquitination and subsequent degradation of p53/TP53 (PubMed:25591766). Mediates ubiquitination and subsequent degradation of JAK1 (PubMed:26027934). Acts as a positive regulator of T-cell activation (PubMed:15843525)
RNF125 · Q96EQ8

Mean pLDDT
77.4/ 100
Confident
232 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0